Refining and accelerating targeted customer re-engagement programs launched in the second half of 2025. These efforts focus on practices where the company provides clinical outcome reviews, targeted IOL counseling training, refresher education, and in-person workflow support.

Expected impact: Stabilize and increase Light Adjustable Lens (LAL) utilization rates within the existing installed base of Light Delivery Devices (LDDs).

Expanding the global footprint of the RxSight system in select international markets where regulatory approvals are held (including North America, Europe, Singapore, South Korea, Australia, and New Zealand) by establishing clinical, commercial, and operational infrastructure.

Expected impact: Establish a durable foundation for long-term growth outside the U.S., where approximately 78% of premium IOL procedures occur.

Consistently investing in research and development to improve LAL performance, refine light-delivery technology, streamline clinical workflows, and support lifecycle management.

Expected impact: Extend LAL applicability, enhance customer experience, and reduce manufacturing costs over time.